impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis

1, 2, 3, 4, 5, 6, 7, 8, 9

 

  1. Division of Rheumatology, Department of Internal Medicine IV, University of Munich, Munich, Germany.
  2. University of L’Aquila, L’Aquila, Italy.
  3. Ortopedyczno-Rehabilitacyjny Szpital Kliniczny, Poznań, Wielkopolskie, Poland.
  4. University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  5. Medical University of Innsbruck, Innsbruck, Austria.
  6. Merck & Co., Inc., Whitehouse Station, NJ, USA.
  7. MSD Italy, Rome, Italy.
  8. MSD Belgium, Brussels, Belgium.
  9. Merck & Co., Inc., Whitehouse Station, NJ, USA.

CER7744
2015 Vol.33, N°2
PI 0201, PF 0208
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 25664404 [PubMed]

Received: 14/07/2014
Accepted : 01/12/2014
In Press: 29/01/2015
Published: 09/04/2015

Abstract

OBJECTIVES:
To evaluate factors influencing injection patterns and patient evaluations of an autoinjector device in biologic-naïve patients beginning golimumab (GLM) treatment.
METHODS:
GO-MORE was an open-label, multinational, prospective study in patients with active rheumatoid arthritis (RA) (28-joint disease activity score based on erythrocyte sedimentation rate [DAS28-ESR] ≥3.2). Patients injected 50 mg subcutaneous GLM once monthly for 6 months. Patients reported use preferences and autoinjector evaluations by questionnaire. Responses were analysed descriptively. Effects of patient variables were evaluated with chi-square tests or t-tests.
RESULTS:
Of 3,280 efficacy-evaluable patients, 67.7% self-injected with the autoinjector. Compared with patients who self-injected, patients who had someone else administer injections had greater baseline disease activity (e.g., DAS28-ESR 5.84 vs. 6.23, respectively), but not more tender/swollen joints in hands/wrists. Month 6 efficacy was greater for patients who self-injected. In those who self-injected, injection site (thigh [75.2%; 1,563/2,077], abdomen [17.4%; 363/2,077], upper arm [7.2%; 151/2,077]) was not associated with wrist swelling or tender/swollen joints in the hand used for injection. Autoinjector ratings were similar across injection sites, yet less pain/discomfort was associated with abdomen injection. Patient autoinjector ratings were favourable overall (e.g. ease of use, pain). Patients with baseline functional impairment had slightly less favourable ratings.
CONCLUSIONS:
Biologic-naïve patients who self-injected had less baseline disease activity and higher response rates than patients who did not self-inject. Although patients prefer to inject in the thigh, injection in the belly may be less painful. Most patients who self-injected had favourable autoinjector evaluations; patients with functional impairment had slightly less favourable ratings.

Rheumatology Article